Form 4: Arteris Director Sells Over 109K Shares Via 10b5-1 Plan

An Arteris, Inc. director sold 109,721 shares of common stock in early March 2026 through a pre-arranged 10b5-1 trading plan.

Summary

• Saiyed Atiq Raza, a Director of Arteris, Inc. (AIP), reported two sales of common stock.
• On March 2, 2026, 106,031 shares were sold at a weighted average price of $17.2127 per share, with prices ranging from $17.00 to $17.67.
• On March 4, 2026, an additional 3,690 shares were sold at a weighted average price of $17.0153 per share, with prices ranging from $17.00 to $17.07.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Mr. Raza on November 7, 2025.
• Following these sales, Mr. Raza directly holds 20,839 shares of Common Stock and indirectly holds 390,000 shares through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the 10b5-1 plan mitigates the immediate concern of opportunistic selling, the significant volume of shares sold by a director suggests a potential lack of strong conviction in future price appreciation.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new, negative information.

Negatives

• A director selling a significant number of shares (109,721 shares) could be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock is fully valued.
• The sales occurred at prices between $17.00 and $17.67, which might be seen as the director taking profits.

Industry Context

StockSavvy.ai notes that insider sales, even those pre-scheduled under 10b5-1 plans, are routinely monitored by investors for insights into management's perception of a company's valuation and future prospects. While 10b5-1 plans mitigate the immediate negative signal, significant sales can still raise questions, especially if the company operates in a competitive or rapidly evolving sector like semiconductor IP or EDA tools, where Arteris is positioned.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

While the insider sale by a director is a negative signal, the transaction was pre-planned under a 10b5-1 plan, which reduces the urgency of the negative interpretation. Without additional context on the company's fundamentals or other market factors, a 'hold' recommendation is appropriate, advising investors to monitor future developments and company performance rather than making an immediate 'sell' decision based solely on this insider transaction.

Keywords

Arteris Inc., AIP, Insider Sale, Form 4, Saiyed Atiq Raza, Director, Stock Transaction, 10b5-1 Plan, Equity Sales